Open AccessUse of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post–kidney Transplantation: A Consecutive Series of 15 Cases
Author(s) -
Ek Khoon Tan,
Andrew Bentall,
Patrick G. Dean,
Mohammed F Shaheen,
Mark D. Stegall,
Carrie A. Schinstock
Publication year - 2019
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000002639
Subject(s) - eculizumab , medicine , plasmapheresis , interquartile range , renal function , kidney transplantation , retrospective cohort study , biopsy , transplantation , kidney , surgery , immunosuppression , gastroenterology , urology , antibody , immunology , complement system
Active antibody-mediated rejection (AMR) that occurs during the amnestic response within the first month posttransplant is a rare but devastating cause of early allograft loss after kidney transplant. Prior reports of eculizumab treatment for AMR have been in heterogeneous patient groups needing salvage therapy or presenting at varied time points. We investigated the role of eculizumab as primary therapy for active AMR early posttransplant.